Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Get your full text copy in PDF

Serum Nesfatin-1 is Reduced in Type 2 Diabetes Mellitus Patients with Peripheral Arterial Disease

Shimei Ding, Wei Qu, Shuangsuo Dang, Xuan Xie, Jing Xu, Yuhuan Wang, Aiyu Jing, Chunhong Zhang, Junhong Wang

(Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi, China (mainland))

Med Sci Monit 2015; 21:987-991

DOI: 10.12659/MSM.892611

Background: Nesfatin-1, recently identified as a satiety regulator, elicits an anti-atherosclerosis effect. Our study was designed to determine whether there is an association between serum nesfatin-1 and the development and severity of peripheral arterial disease (PAD) in patients with type 2 diabetes mellitus (T2DM).
Material and Methods: This cross-sectional study included 355 T2DM patients (200 without PAD and 155 with PAD).
Results: T2DM patients with PAD exhibited marked lower serum nesfatin-1 concentrations than those without PAD. Multivariable logistic regression analysis indicated an inverse association of serum nesfatin-1 concentrations with the development of PAD in T2DM patients (OR 0.008, 95% CI 0.002 to 0.028; P<0.001). Simple linear regression analysis showed a marked correlation between serum nesfatin-1 concentrations and body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), C-reactive protein (CRP), and ankle-brachial index (ABI) in T2DM patients. By contrast, multivariable analysis showed only BMI and ABI as independent correlates of serum nesfatin-1.
Conclusions: Our study shows an association of serum nesfatin-1 concentrations and the development and severity of PAD in T2DM patients.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree